The value of immunotherapy in head and neck cancer.
Paolo MancaLuis E RaezMatthew SalzbergJorge SanchezBrian HunisChristian C RolfoPublished in: Expert opinion on biological therapy (2018)
The challenges that need to be addressed in order to maximize the benefits of immunotherapy in HNSCC are the selection criteria for immune checkpoint inhibitors and the optimization of combination regimens of immunotherapeutics or chemo-immunotherapy. Furthermore, there remains to be a lack of knowledge in how to incorporate molecular biomarkers as predictors of response to HNSCC immunotherapy.